Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Salicylic acid; Wool alcohols ointment
Thornton & Ross Ltd
D01AE12
Salicylic acid; Wool alcohols ointment
20mg/1gram ; 980mg/1gram
Ointment
Cutaneous
No Controlled Drug Status
Valid as a prescribable product
BNF: ; GTIN: 5011309193718
SALICYLIC ACID OINTMENT Read the complete document
OBJECT 1 SALICYLIC ACID OINTMENT BP Summary of Product Characteristics Updated 27-Feb-2018 | Thornton & Ross Ltd 1. Name of the medicinal product Salicylic Acid Ointment BP 2. Qualitative and quantitative composition Salicylic acid BP 2.0% w/w 3. Pharmaceutical form Ointment. 4. Clinical particulars 4.1 Therapeutic indications For the treatment of hyperkeratotic and scaling conditions such as psoriasis. 4.2 Posology and method of administration Topical. Recommended dose and dosage schedule Adults, children and the elderly: apply twice daily to the affected area. 4.3 Contraindications Contraindicated in patients displaying salicylate hypersensitivity, or sensitivity to any other ingredient in the preparation. 4.4 Special warnings and precautions for use For external use only. Avoid contact with broken or inflamed skin. Salicylate toxicity may occur if applied to large areas of skin or to the skin of neonates. 4.5 Interaction with other medicinal products and other forms of interaction There are no known interactions when used as indicated. However, topical salicylic acid may increase the absorption of other topically applied medicines. Concomitant use of Salicylic Acid Ointment BP and other topical medicines on the same area of skin should therefore be avoided. 4.6 Fertility, pregnancy and lactation Whilst there are no known contra-indications to the use of Salicylic Acid Ointment BP during pregnancy and lactation, the safety has not been established. Salicylic Acid Ointment BP should therefore be used with caution or following professional advice. 4.7 Effects on ability to drive and use machines None likely. 4.8 Undesirable effects Possible sensitivity reactions, drying and irritation. REPORTING OF SUSPECTED ADVERSE REACTIONS Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: ww Read the complete document